TOYO Pitches HJT U.S. Cell Expansion After Revenue Surge, but Margin and Balance-Sheet Risks Persist

What happened

TOYO used its Solar Analyst Day to highlight an 88% year-over-year revenue jump in the first half and to lay out plans for a proposed heterojunction (HJT) solar cell facility in the U.S., building on its existing TOPCon capacity in Vietnam and Ethiopia. However, the master report notes that this segment has historically been margin-dilutive, with 2024 operating income falling despite revenue growth and 1H25 gross margin compressing to 16.6% from 19.3% as higher input costs and opex eroded profitability. The HJT expansion represents a significant new capital commitment at a time when TOYO already carries a working-capital deficit of roughly $70 million, an auditor going-concern warning, and a net debt/EBITDA of 1.85. The analyst day also serves to promote the U.S. manufacturing story and Section 45X credits, but the company has yet to demonstrate sustained positive free cash flow or a reduction in customer concentration (VSUN still accounted for 66% of 2024 revenue). While the revenue growth is a positive sign for demand, the market has not yet priced in the full execution and liquidity risk, and the proposed HJT facility adds another layer of capital intensity to an already leveraged business model.

Implication

The 88% revenue growth in the first half indicates that TOYO's expanded capacity is finding buyers, but it does not address the structural margin compression and operating leverage issues that the master report flags as the core challenge. The proposed HJT solar cell facility would require substantial additional capital, and given the company's existing working-capital deficit and going-concern language, it is more likely to be funded with debt or equity issuance, which would be dilutive or increase financial risk. The master report's STRONG SELL rating with a conviction of 4 out of 5 is reinforced by the fact that even an 88% revenue jump does not necessarily translate into meaningful net income, as seen in prior periods where net income was inflated by one-off items or eroded by opex. Investors should treat the analyst day's emphasis on U.S. expansion and Section 45X credits as promotional until TOYO demonstrates consecutive quarters of positive free cash flow, margin recovery above 20%, and a clear path to reducing related-party dependence. Accordingly, at a share price near $6, the risk/reward remains unfavorable; the attractive entry identified in the master report is around $3.75, and only a sustained improvement in profitability and balance-sheet metrics would warrant a reassessment.

Thesis delta

The thesis's bear case remains dominant. The 88% revenue jump confirms volume uptake, but the simultaneous announcement of a new HJT cell facility increases capital intensity and execution risk, which offsets the demand strength. Thus the STRONG SELL rating remains unchanged, with the main catalyst still being whether FY25/FY26 results show sustained net margin above 10% without equity raise.